Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
By Justice Department, Drug Enforcement Administration · Nov 9, 2026, 11:00 PM CST
The Drug Enforcement Administration (DEA) is adjusting the 2026 aggregate production quota for the schedule II controlled substances d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). In making this determination, DEA has considered the factors set forth in 21 CFR 1303.13(b) in accordance with 21 U.S.C. 826(a) and is expediting publication of this determinati
Excerpt shown under fair-use limits. Full text remains with the original publisher.
Layer 1 · Claims & fact checks
AI analysisLayer 3 · Reporting analysis
AI analysisFormalThe statement uses formal, bureaucratic language to convey an official regulatory action.
CitationThe passage cites specific statutes and regulations to legitimize the action and demonstrate compliance.
Context
AI analysisMissing context
The announcement does not provide the specific quota amounts, the reasons for the adjustment, the expected impact on manufacturers or patients, or any stakeholder input.
Important context
The adjustment follows statutory requirements (21 CFR 1303.13(b), 21 U.S.C. 826) that guide DEA's quota-setting process for schedule II substances, which are tightly regulated due to their potential for abuse.
Opinion vs. reporting
AI analysisThe text is purely factual reporting of an agency action; it contains no opinion.